Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06961370 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
A Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
- 16
- Study locations
NCT06961370: Recruiting Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, sponsored by Hoffmann-La Roche.
NCT06961370 is a Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 132 participants, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (91% lower). The trial reports 16 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06961370, a Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
- 16
- Study locations
Study Summary
The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral intravitreal (IVT) doses.
Conditions Studied
Interventions
- DRUG RO7669330
- DRUG Syfovre™
- DRUG Izervay™
Study Locations (16)
Texas
- Austin Clinical Research, LLC - Austin
- Texas Retina Associates - Dallas
- Retina Consultants of Texas Westover Hills Retina Center - San Antonio
- Retina Consultants of Texas - (The Woodlands) - The Woodlands
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
- Global Research Management - Glendale
- Retinal Consultants Medical Group Inc - Parkcenter Drive - Sacramento
Arizona
- Associated Retina Consultants - Phoenix - DocTrials - PPDS - Phoenix
- Barnet Dulaney Perkins Eye Center - Sun City
Tennessee
- Charles Retina Institute - Germantown
- Tennessee Retina PC - Nashville
Georgia
- Southeast Retina Center - Augusta
Maryland
- Cumberland Valley Retina Consultants PC - Hagerstown
Missouri
- The Retina Institute - St Louis
Oregon
- Retina Northwest - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2025-07-16 |
| Est. Completion | 2027-01-03 |
| Phase | Phase 1 |
What NCT06961370 shows while recruiting
NCT06961370 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which RO7669330 is the first listed.
NCT06961370 lists 16 locations in 9 states (Texas, California, Arizona).
Frequently Asked Questions
What is clinical trial NCT06961370 about?
NCT06961370 is a clinical study titled "A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)". The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral intravitreal (IVT) doses.
What is the current status of trial NCT06961370?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2025-07-16. Estimated completion is 2027-01-03.
What conditions does trial NCT06961370 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, Geographic Atrophy.
What interventions are being tested in trial NCT06961370?
The interventions under investigation include: RO7669330 (DRUG), Syfovre™ (DRUG), Izervay™ (DRUG).
Who is sponsoring clinical trial NCT06961370?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06961370 being conducted?
This trial has 16 study locations across Arizona, California, Georgia, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06961370's enrollment target sits among peer trials
132 22nd of 74 higher than 53 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 1
-
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
-
A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI